Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $5.83

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.00.

A number of brokerages have issued reports on ZNTL. Guggenheim lifted their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Zentalis Pharmaceuticals by 31.4% in the third quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company’s stock worth $1,092,000 after purchasing an additional 172,628 shares during the last quarter. Anfield Capital Management LLC raised its position in Zentalis Pharmaceuticals by 239.9% in the 4th quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock worth $328,000 after buying an additional 171,228 shares during the last quarter. SG Americas Securities LLC raised its position in Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $37,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Zentalis Pharmaceuticals by 182.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock valued at $634,000 after acquiring an additional 175,771 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.09 on Friday. Zentalis Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $6.95. The firm has a market cap of $291.15 million, a price-to-earnings ratio of -2.36 and a beta of 1.99. The company has a 50-day moving average of $3.47 and a 200 day moving average of $2.49.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -1.94 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.